Squadron Capital Management LLC holds a focused book of 30 stocks worth $250.0M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened NEKTAR THERAPEUTICS and trimmed ABIVAX SA. Their largest long position is RELMADA THERAPEUTICS INC at 24% of the equity book. They also disclosed $8.2M in put options (a bearish bet) and $14.8M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2050709/holdings"
Use Arkolith to show Squadron Capital Management LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
0% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Relmada Therapeutics Inc COM | $59.0M | 8.47M | 23.6% | ▲+26% Added · +1.8M sh | |
| 2 | Cogent Biosciences Inc COM | $30.3M | 787.5K | 12.1% | ▲+1.0% Added · +7K sh | |
| 3 | Kalvista Pharmaceuticals Inc COM | $19.8M | 985.1K | 7.9% | ▲+41% Added · +285K sh | |
| 4 | Kodiak Sciences Inc COM | $14.5M | 380.0K | 5.8% | ▲+30% Added · +88K sh | |
| 5 | Abivax Sa SPONSORED ADS | $14.5M | 130.0K | 5.8% | ▼−10% Reduced · −15K sh | |
| 6 | Edgewise Therapeutics Inc COM | $11.0M | 350.0K | 4.4% | —Held | |
| 7 | Nektar Therapeutics COM NEW | $9.0M | 125.0K | 3.6% | ▲New New position | |
| 8 | Adlai Nortye Ltd SPONSORED ADS | $8.8M | 1.27M | 3.5% | ▲New New position | |
| 9 | Zentalis Pharmaceuticals Inc COM | $8.5M | 3.63M | 3.4% | ▲New New position | |
| 10 | Maze Therapeutics Inc COM | $7.7M | 257.5K | 3.1% | ▼−47% Reduced · −233K sh | |
| 11 | Scynexis Inc COM NEW | $7.0M | 7.61M | 2.8% | ▲New New position | |
| 12 | Relay Therapeutics Inc COM | $6.7M | 672.5K | 2.7% | ▲New New position | |
| 13 | C4 Therapeutics Inc COM STK | $5.9M | 2.25M | 2.4% | ▲New New position | |
| 14 | Inhibikase Therapeutics Inc COM NEW | $5.9M | 3.50M | 2.4% | ▼−17% Reduced · −725K sh | |
| 15 | Palisade Bio Inc COM | $5.3M | 3.00M | 2.1% | ▼−33% Reduced · −1.5M sh | |
| 16 | Eupraxia Pharmaceuticals Inc COM | $4.9M | 680.0K | 2.0% | ▲+36% Added · +180K sh | |
| 17 | GH Research PLC ORDINARY SHARES | $4.6M | 325.0K | 1.8% | ▲+3.2% Added · +10K sh | |
| 18 | Promis Neurosciences Inc COM SHS | $4.1M | 325.0K | 1.7% | ▲New New position | |
| 19 | Lipocine Inc New COM NEW | $3.6M | 450.0K | 1.4% | ▼−15% Reduced · −80K sh | |
| 20 | Inventiva Sa ADS | $3.0M | 535.0K | 1.2% | ▲+78% Added · +235K sh | |
| 21 | Alx Oncology Hldgs Inc COM | $2.9M | 1.46M | 1.2% | ▲New New position | |
| 22 | Context Therapeutics Inc COM | $2.9M | 1.10M | 1.2% | ▲New New position | |
| 23 | Nextcure Inc COM NEW | $2.8M | 265.0K | 1.1% | ▲+12% Added · +28K sh | |
| 24 | Sol-Gel Technologies Ltd SHS NEW | $2.5M | 31.0K | 1.0% | ▲New New position | |
| 25 | Pasithea Therapeutics Corp COM NEW | $1.6M | 2.10M | 0.6% | —Held | |
| 26 | Traws Pharma Inc COM NEW | $936K | 511.7K | 0.4% | ▼−28% Reduced · −202K sh | |
| 27 | Therapeuticsmd Inc COM NEW | $849K | 420.4K | 0.3% | ▲New New position | |
| 28 | Spruce Biosciences Inc COM NEW | $797K | 12.2K | 0.3% | ▼−83% Reduced · −58K sh | |
| 29 | Werewolf Therapeutics Inc COM | $469K | 563.5K | 0.2% | ▲New New position | |
| 30 | Neuphoria Therapeutics Inc COM | $312K | 76.7K | 0.1% | ▲New New position |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | KALVISTA PHARMACEUTICALS INC | $6.3M | 315K |
| PUT · bearish | KARYOPHARM THERAPEUTICS INC | $4.2M | 750K |
| PUT · bearish | IDEAYA BIOSCIENCES INC | $4.0M | 120K |
| CALL · bullish | IDEAYA BIOSCIENCES INC | $3.5M | 104K |
| CALL · bullish | ARRIVENT BIOPHARMA INC | $2.5M | 110K |
| CALL · bullish | RELAY THERAPEUTICS INC | $1.5M | 150K |
| CALL · bullish | ZENTALIS PHARMACEUTICALS INC | $936K | 400K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.